Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy

References

• Chan GC, Tang SC. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol Dial Transplant. 2015. [Epub ahead of print]. doi:10.1093/ndt/gfu411
   Google Scholar
• Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, et al. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015;2015:948417
   PubMed Web of Science ®Google Scholar
• Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 2015;6:3–15
   PubMed Web of Science ®Google Scholar
• Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: Present and future. World J Diabetes. 2014;5:763–776
   PubMedGoogle Scholar
• Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab Syndr. 2015. [Epub ahead of print]. doi: 10.1016/j.dsx.2015.02.008
   Google Scholar
• Lloyd A, Komenda P. Optimizing care for Canadians with diabetic nephropathy in 2015. Can J Diabetes. 2015;39:221–8
   PubMed Web of Science ®Google Scholar
• Jin H, Piao SG, Jin JZ, et al. Synergistic effects of leflunomide and benazepril in streptozotocin-induced diabetic nephropathy. Nephron Exp Nephrol. 2014;126:148–156
   PubMed Web of Science ®Google Scholar
• Russo PA, Wiese MD, Smith MD, et al. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: A pharmacokinetic and pharmacogenetic study. Ann Pharmacother. 2013;47:e15
   PubMed Web of Science ®Google Scholar
• Chon WJ, Josephson MA. Leflunomide in renal transplantation. Expert Rev Clin Immunol. 2011;7:273–281
   PubMed Web of Science ®Google Scholar
• Wang J, Liu H, Li N, et al. The protective effect of fucoidan in rats with streptozotocin-induced diabetic nephropathy. Mar Drugs. 2014;12:3292–3306
   PubMed Web of Science ®Google Scholar
• Tonolo G, Cherchi S. Tubulointerstitial disease in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2014;7:107–115
   PubMedGoogle Scholar
• Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21:79–85
   PubMed Web of Science ®Google Scholar
• Nielsen SE, Sugaya T, Tarnow L, et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009;32:1684–1688
   PubMed Web of Science ®Google Scholar
• Peng T, Wang J, Zhen J, et al. Effect of benazepril on the transdifferentiation of renal tubular epithelial cells from diabetic rats. Biomed Rep. 2014;2:490–494
   PubMedGoogle Scholar
• Duan SB, Liu GL, Wang YH, Zhang JJ. Epithelial-to-mesenchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats. Ren Fail. 2012;34:1244–1251
   PubMed Web of Science ®Google Scholar
• Awad AS, Kinsey GR, Khutsishvili K, et al. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol. 2011;301:F1358–F1366
   Google Scholar
• Nicholas SB, Liu J, Kim J, et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int. 2010;77:588–600
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Igarashi M, Hirata A, et al. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J. 2004;51:499–504
   PubMed Web of Science ®Google Scholar
• Persy VP, Verhulst A, Ysebaert DK, et al. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int. 2003;63:543–553
   PubMed Web of Science ®Google Scholar
• Yano R, Golbar HM, Izawa T, et al. Participation of bone morphogenetic protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat renal fibrosis. Exp Toxicol Pathol. 2015;67:99–107
   PubMed Web of Science ®Google Scholar
• Kashiwagi E, Tonomura Y, Kondo C, et al. Involvement of neutrophil gelatinase-associated lipocalin and osteopontin in renal tubular regeneration and interstitial fibrosis after cisplatin-induced renal failure. Exp Toxicol Pathol. 2014;66:301–311
   PubMed Web of Science ®Google Scholar
• Irita J, Okura T, Jotoku M, et al. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol. 2011;301:F833–F844
   Google Scholar
• Lan HY. Transforming growth factor-β/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol. 2012;39:731–738
   PubMed Web of Science ®Google Scholar
• Li L, Yin Q, Tang X, et al. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway. PLoS One. 2014;9:e113639
   PubMed Web of Science ®Google Scholar
• Shaker OG, Sadik NA. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy. Hum Exp Toxicol. 2013;32:1089–1096
   PubMed Web of Science ®Google Scholar
• Wang JY, Gao YB, Zhang N, et al. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol. 2014;392:163–172
   PubMed Web of Science ®Google Scholar
• Ina K, Kitamura H, Tatsukawa S, Fujikura Y. Significance of α-SMA in myofibroblasts emerging in renal tubulointerstitial fibrosis. Histol Histopathol. 2011;26:855–866
   PubMed Web of Science ®Google Scholar
• Badid C, Desmouliere A, Babici D, et al. Interstitial expression of alpha-SMA: An early marker of chronic renal allograft dysfunction. Nephrol Dial Transplant. 2002;17:1993–1998
   PubMed Web of Science ®Google Scholar
• Sawashima K, Mizuno S, Mizuno-Horikawa Y, et al. Expression of alpha-smooth muscle actin and fibronectin in tubulointerstitial lesions of cats with chronic renal failure. Am J Vet Res. 2000;61:1080–1086
   PubMed Web of Science ®Google Scholar